Details of the Drug

General Information of Drug (ID: DMW1NKO)

Drug Name
X-82
Indication
Disease Entry ICD 11 Status REF
Age-related macular degeneration 9B75.0 Phase 2 [1]
Macular degeneration 9B78.3 Phase 1 [2]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
59215954
TTD ID
D0L2ZY
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-derived growth factor receptor (PDGFR) TTI2WET NOUNIPROTAC Modulator [3]
Vascular endothelial growth factor receptor (VEGFR) TTVJ1D8 NOUNIPROTAC Inhibitor [4]
Vascular endothelial growth factor receptor 1 (FLT-1) TT2Q6G1 VGFR1_HUMAN Modulator [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Age-related macular degeneration
ICD Disease Classification 9B75.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 1 (FLT-1) DTT FLT1 4.94E-03 0.74 1.24
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02348359) X-82 to Treat Age-related Macular Degeneration. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Tyrogenex.
3 National Cancer Institute Drug Dictionary (drug id 695817).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)